VTGN Receives FDA Study May Proceed for Refisolone IND, Phase 2 Hot Flash Program Enabled, 80% Frequency Reduction in Phase 2a Study
Vistagen Therapeutics, Inc. Common Stock · Now $0.65
+4.9% in 3d after detection
Post-detection moves
1h
—
1d
-0.1%
3d
+4.9%
7d
-1.6%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS